We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company") today announced the closing of its initial public offering of 7,187,500 shares of its common stock at a public offering price of $4.00 per share.